Drugs / pathogen-specific CTLs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03159364 | Jun 2026 → Dec 2029 expected | Epstein-Barr virus infection, adenoviridae infectious disease, cytomegalovirus infection, fungal infectious disease +2 | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pathogen-specific CTLs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03159364 ↗ |
| Known as | microbial-specific cytotoxic T lymphocytes | “In this study, the safety and efficacy of microbial-specific cytotoxic T lymphocytes (CTLs) will be investigated.” NCT03159364 ↗ |
| Modality | Cell therapy | “Adoptive immunotherapy with cytotoxic T lymphocytes (CTLs) reactive with specific microbial antigens” NCT03159364 ↗ |
| Route | Intravenous | “via IV injection” NCT03159364 ↗ |